Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries

Circulation

Volumn 97, Issue 25, 1998, Pages 2519-2526

  Kugiyama, Kiyotaka ^a   Doi, Hideki ^a   Motoyama, Takeshi ^a   Soejima, Hirofumi ^a   Misumi, Kenji ^a   Kawano, Hiroaki ^a   Nakagawa, Osamu ^a   Yoshimura, Michihiro ^a   Ogawa, Hisao ^a   Matsumura, Toshiyuki ^a   Sugiyama, Seigo ^a   Nakano, Takamitsu ^b   Nakajima, Katsuyuki ^b   Yasue, Hirofumi ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

Author keywords

Acetylcholine; Endothelium; Endothelium derived factors; Hyperlipoproteinemia; Lipoproteins

Indexed keywords

ACETYLCHOLINE; MONOCLONAL ANTIBODY; TRIACYLGLYCEROL;

ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ANTIBODY AFFINITY; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; VASOMOTOR REFLEX;

EID: 0032581015     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.25.2519     Document Type: Article

References (24)

1. Yasue H, Matsuyama K, Matsuyama K, Okumura K, Morikami Y, Ogawa H. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment: possible role of early coronary atherosclerosis. Circulation. 1990;81:482-490.
2. Zeiher AM, Drexler H, Saurbrier B, Just H. Endothclium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest. 1993;92:652-662.
3. Vanhoutte PM. The endothelium: modulator of vascular smooth muscle tone. N Engl J Med. 1988;319:512-513.
4. Moncada S, Palmer RMJ, Higgs EA. NO: physiology, paihophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
5. Kugiyama K, Yasue H, Ohgushi M, Motoyama T, Kawano H, Inobe Y, Hirashima O, Sugiyama S, Deficiency in NO bioaclivity in epicardial coronary arteries of cigarette smokers. J Am Coll Cardiol. 1996;28: 1161-1167.
6. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III. NO activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995; 95:1747-1755.
7. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-485.
8. Patsh JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsh W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
9. Austin MA. Plasma triglyceride and coronary heart disease. Anerioscler Thromb. 1991;11:2-14.
10. Wilson PWF, Anderson KM, Castelli WP. The impact of triglycerides on coronary heart disease: the Framingham Study. In: Gotto AM Jr, Paoletti R, eds. Atherosclerosis Reviews. New York, NY: Raven Press; 1991;22: 59-63.
11. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
12. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhom DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mid/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of losaslatin. Circulation. 1994;90:42-49.
13. Ellsworth JL, Kraemer FB, Cooper AD, Transport of β-very low density lipoproteins and chylomicron remnants by macrophages is mediated by the low density lipoprotein receptor pathway. J Biol Chem. 1987;262: 2316-2325.
14. Nestel P, Billington T, Tada N, Nugenl P, Fidge N. Heterogeneity of very-low-density lipoprotein metabolism in hyperlipidemic subjects. Metabolism. 1983;32:810-817.
15. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoprotein isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res. 1992;33:369-380.
16. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A. Tada N, Nakamura H, Campos E, Havel RJ. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti-apoB-100 and anti-apoA-1 immunoaffinity mixed gels. Clin Chim Acta. 1993;223:53-71.
17. Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A. 1993;90:2069-2073.
18. Nakajima K, Okazaki M, Tanaka A, Pullinger CR, Wang T, Nakano T, Adachi M, Havel RJ. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apoB-100 and apoA-1. J Clin Ligand Assay. 1996;19:177-183.
19. WHO Expert Committee on Diabetes Mellitus. Second Report: World Health Organization Tech Report Series 646. Geneva, Switzerland: World Health Organization: 1980.
20. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, Miyauchi K. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated α-cyclodextrin. Clin Chem. 1995;41:717-723.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin Chem. 1972;18:449-502.
22. Wikinski RLW, Schreier LE, Rosenthal SB. New method for isolating and quantifying intermediate and β-very-low-density lipoprotein cholesterol. Clin Chem. 1991;37:1913-1916.
23. Windler E, Chao Y-s, Havel RJ. Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem. 1980;255:5475-5480.
24. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol. 1994;5:102-109.